CAR-T - MM+M - Medical Marketing and Media

CAR-T

All articles by CAR-T

As CAR-Ts go from candidates to brands, what’s the marketing strategy?
As CAR-Ts go from candidates to brands, what’s the marketing strategy?
Sony Salzman
February 1, 2018
12:00 pm

Strategies for differentiating CAR-T therapies emerge in the early days of 2018, while competitors race to catch up with Novartis and Gilead.

Five things for pharma marketers to know: Friday, January 19, 2018
Five things for pharma marketers to know: Friday, January 19, 2018
Virginia Lau
January 19, 2018
3:00 pm

Biogen, UCB reportedly showing interest in Acorda acquisition; Kite Pharma and Pfizer to develop combo lymphoma therapy; hospitals to form generics nonprofit

Five things for pharma marketers to know: Thursday, December 21, 2017
Five things for pharma marketers to know: Thursday, December 21, 2017
Virginia Lau
December 21, 2017
3:45 pm

BI to pay $13.5 million for misleading marketing; ICER: CAR-T therapies more cost-effective than chemotherapy; FDA approves Roche’s breast cancer combo therapy

Five things for pharma marketers to know: Tuesday, October 31, 2017
Five things for pharma marketers to know: Tuesday, October 31, 2017
Virginia Lau
October 31, 2017
2:37 pm

Pfizer Q3 revenue driven by Prevnar sales; President Trump’s opioid panel presents draft to combat crisis; Novartis seeks FDA approval for CAR-T therapy Kymriah

Five things for pharma marketers to know: Thursday, October 19, 2017
Five things for pharma marketers to know: Thursday, October 19, 2017
Jaimy Lee
October 19, 2017
1:55 pm

The FDA approves Kite’s CAR-T therapy; Omnicom reports strong Q3 performance for healthcare agencies; Hearst to acquire Rodale, up health presence

Five things for pharma marketers to know: Friday, September 1, 2017
Five things for pharma marketers to know: Friday, September 1, 2017
Jaimy Lee
September 1, 2017
2:10 pm

600 patients are eligible for CAR-T therapy; the FDA halts Keytruda combo study for multiple myeloma; the regulator delays decision on Herceptin biosimilar

Novartis’ CAR-T therapy, now approved, faces questions about price and side effects
Novartis’ CAR-T therapy, now approved, faces questions about price and side effects
Kevin McCaffrey
August 30, 2017
9:19 pm

The Swiss drugmaker is the first to receive FDA approval to market a CAR-T therapy.

Five things for pharma marketers to know: Monday, August 28, 2017
Five things for pharma marketers to know: Monday, August 28, 2017
Kevin McCaffrey
August 28, 2017
2:36 pm

Gilead to acquire Kite; the FDA issues fewest number of warning letters since 2008; the regulator approves BI’s Humira biosimilar

Five things for pharma marketers to know: Wednesday, August 23, 2017
Five things for pharma marketers to know: Wednesday, August 23, 2017
Jaimy Lee
August 23, 2017
2:00 pm

Doctors fret about price of Novartis’ experimental CAR-T therapy; study finds digital pillboxes don’t improve adherence; India awards Pfizer vaccine patent

Novartis’ CAR-T therapy gets nod from FDA committee
Novartis’ CAR-T therapy gets nod from FDA committee
Jaimy Lee
July 13, 2017
1:55 pm

The drugmaker is one step closer to a potential approval of its experimental cancer treatment.

  • Culture drives the company

    Get to know each of these companies by learning about their culture, work/life balance, D&I initiatives and more.

  • From Our Partners